To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess
the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor
CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.